Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Parallel Session 4417

Genetics: New Therapeutics and Treatments

Wednesday, October 7, 2026
14:00 - 15:30 | Conference Room North 203, Level 2

In this session we will review novel therapeutic approaches to movement disorders using genetic interventions. Specifically, we will review RNA interference (RNAi) interventions, antisense oligonucleotides (ASO) and gene editing.

Chairs:

Roy Alcalay, Israel
Christine Klein, Germany

Presenters:

RNA Interference (RNAi) Interventions
Nurit Omer, Israel

Antisense Oligonucleotides (ASO)
Jinkuk Kim, Korea

Gene Editing and Gene Replacement
Manju Kurian, United Kingdom

CSPC Liaison(s):

Roy Alcalay, Israel

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Describe the mechanism of RNAi and the latest trials in Huntington’s, Parkinson’s and other movement disorders
  2. Describe the mechanism of ASO and the latest in common and rare movement disorders
  3. Describe existing therapies and experimental therapies modifying and editing genes

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced